Grant Opportunities

We fund research that will promote advances in the treatment and management of Kabuki syndrome across the lifespan. Research completed in cross-institutional collaborations can accelerate timelines, promote efficiency, and make a larger impact across the Kabuki syndrome community.

This year, we’re thrilled to offer two grant opportunities totaling up to $750,000 in funding for Kabuki syndrome research.


Be Notified of Future Grants

2024 Therapy Development Fund

This fund supports grants focused on advancing therapies for Kabuki syndrome (KS) in the pipeline towards IND-filing and clinical trials.

  • Eligibility: Applicants are expected to have already identified one or more potential therapeutic candidates for KS. Applications are encouraged from all qualified individuals worldwide, from both academia and industry. 
  • Funding Amount and Duration: Each grant will average between $150,000 and $250,000. KSF does not fund indirect costs or overhead. 
  • Requirements: Applicants will be required to submit a comprehensive application that includes the detailed study design, budget, timelines, key milestones and deliverables for the proposed study(ies) that will be conducted using the fund, as well as proof of concept data that have already been collected to support the feasibility and efficacy of their proposed treatments, and a comprehensive preclinical drug development plan that outlines all the necessary future studies that are required for IND submission.
  • Submission Deadlines: Letters of intent are due by July 1, 2024. Full applications must be submitted by September 1, 2024. 
Application GuidelinesLetter of Intent Template

2024 Discovery Grant

This Grant program aims to accelerate research that enables Kabuki syndrome (KS) therapeutic discovery.

Prospective applicants may submit proposals aimed at the identification or development of: 1) endpoints/ biomarkers/ outcome measures AND/ OR 2) potential druggable targets for therapeutic development. The outcome of the two year project must be translational in nature such as the validation of identified biomarkers for use in clinical trials, the development of novel therapeutic targets with clear potential for intervention, or the advancement of preclinical studies that bridge the gap between basic research findings and clinical application. 

  • Eligibility: Applicants must form teams composed of two or more people based at two or more research or academic institutions, biotechnology or pharmaceutical companies. Academic and industry collaborations are strongly encouraged to foster synergy between academia and industry, promoting translational research and the potential for impactful outcomes. Recipients of current Discovery grants cannot apply until the expiration of their current grant.
  • Funding Amount and Duration: Maximum of $150,000 over two years. Lower funding requirements that can achieve the objectives would be appreciated. KSF is also able to co-fund with other granting organizations, or add to funding from other organizations that would improve outcomes or accelerate timelines. KSF does not fund indirect costs or overhead.
  • Submission Deadline: Full applications must be submitted by July 9, 2024.
Application GuidelinesApplication Template

Discovery Grant Timeline

New to this year’s Discovery Grant, applicants were able to chose one of two options: 

  • Academic and industry partners submitted a joint letter of intent (LOI) by April 8, 2024, which was reviewed by KSF. Those that meet program specifications were approved to submit a full application.
  • Alternatively, to facilitate collaborations, KSF held a virtual ‘Pitch&Connect’ meeting on May 15, 2024 for invited industry representatives and academics to pitch their technology platforms and KS research interests and resources, respectively. Meeting participants were encouraged to collaborate, form teams, and jointly develop their full grant applications.

Have a question about this year’s grants? Please contact our team.

The 2023 Discovery Grant: Addressing Knowledge Gaps

We granted $150,000 to a collaborative team seeking to uncover why the symptoms and severity can vary so greatly between people diagnosed with Kabuki syndrome. Discover how this project can open new pathways to treatments: 

Team Members:

  • Dr. Hans Bjornsson, University of Iceland, Johns Hopkins
  • Dr. Karl Broman, University of Wisconsin
  • Dr. Agnes Ulfig, University of Iceland

Project Title: Mapping genetic modifiers in Kabuki syndrome to identify novel therapeutic avenues.

Project Summary: Kabuki syndrome patients with the same genetic variants can exhibit varying degrees of symptom severity, suggesting the presence of genetic factors that can modify the condition’s effects. The project aims to systematically identify these genetic factors that influence the severity of symptoms in Kabuki syndrome using mouse models.  

To explore this, this research team will develop mouse models of Kabuki syndrome with different genetic backgrounds. In current Kabuki syndrome mouse models, each mouse is genetically identical, which is comparable to studying one individual person with Kabuki syndrome.  After creating mice with Kabuki syndrome mutations with different genetic backgrounds, the researchers plan to track their traits to pinpoint which genetic factors influence the symptoms of Kabuki syndrome. 

This research has the potential to explain why there is such variability in symptoms and severity, which is essential for not only a more complete understanding of the syndrome but also the development of more specific and effective therapies. This research could lead to identification of potential therapeutic targets and the development of novel therapeutic strategies.

2023 Discovery Grant Awarded at Annual Research Conference

Watch Dr. Bjornsson accept this well-deserved award on behalf of the team. He illustrates this innovative two-year project that is poised to significantly influence the landscape of Kabuki syndrome treatments. 

Watch on YouTube